Novartis takes home rights to Lubris’ eye drug
Novartis has elected to exercise an option to in-license experimental eye drug ECF843 from US biopharma Lubris.
Read More
Tag: Xiidra
US approves Shire’s eye disease drug
Shire’s Xiidra has been approved by US regulators to treat the signs and symptoms of dry eye disease, giving patients access to the first prescription eye drop specifically approved for the condition.
Read More
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
- Taiwan Bio partners with Terumo to advance automated Treg manufacturing
- Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis
